Buy Proglumide(Milid) at factory price from the Manufacturer & Supplier
Proglumide is a white crystalline powder; odorless and somewhat bitter. Soluble in ethanol or chloroform, very somewhat soluble in water; blended in sodium hydroxide test solution, Are an antacid and a peptic ulcer drug, has been examined in the treatment of peptic ulcer disease, postoperative pain, Huntington's chorea, schizophrenia, gastric carcinoma, and colorectal carcinoma.
Proglumide has a protective effect on the gastric mucosa and stimulates ulcer healing. Applicable to gastric and duodenal ulcer, gastritis, stress ulcer, and so forth, the effective rate of 81-96%, the application of this product does not happen gastric acid rebound, and the recurrence rate is low.
Using glutamic acidity as a starting materials , reacting with benzoyl chloride to obtain N-benzoylglutamic acid solution, Then, acetic anhydride is reacted to obtain N-benzoylglutamic acid anhydride, and then aminated with dipropylamine to obtain proglumide. The total yield is 26-30% based on glutamic acid.
Proglumide has anti-gastrin action, has a better effect on managing gastric acid and suppressing pepsin secretion; and has a protective effect on gastric mucosa and stimulates healing. It can be used for the treatment of gastric ulcer and duodenal ulcer, gastritis, and so forth It has a good impact on the improvement of clinical symptoms of peptic ulcer and the recovery of the ulcer.
This acts as a cholecystokinin antagonist, which blocks both the CCK A and CCK B subtypes. It had been used mainly in the treating stomach ulcers, although it has been largely replaced by newer drugs for this application.
Proglumide has also been shown to behave as a δ-opioid agonist, which might contribute to the analgesic effects.
An interesting side effect of proglumide is that it improves the analgesia produced by opioid drugs, and can prevent or even reverse the development of threshold to opioid drugs. This particular can make it a useful adjuvant treatment to make use of alongside opioid drugs in the treatment of chronic pain conditions such as cancer, where opioid analgesics may be expected for long periods and development of tolerance reduces scientific efficacy of these drugs.
Proglumide also works as a placebo effect amp for pain conditions. When injected visibly to a subject, its analgesic effect is bigger than a likewise administered placebo. When inserted secretly, it does not have any effect, whereas standard pain drugs have an effect, even if they are administered without the subject's awareness.
The particular supposed mechanism is an enhancement of the neural pathways of expectation therefore of dopamine and endogenous opioids being suddenly released throughout numerous structures of the brain and spinal cord.
The ventral tegmental area is the structure believed to mediate proglumides analgesic and euphoric effects, however dozens of areas with a variety of physical and psychological functions are implicated in the mediation of the placebo effect (this accounts for proglumides ability to produce literally measurable effects on essential signs such as center rate, blood pressure, respiration rate, and tidal quantity which can not be accounted for by the clinically insignificant δ-opioid appreciation.
